Abstract:1 Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan 2 Health Services Center, Ehime University, Matsuyama, Japan 3 Department of Lifestyle-related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Toon, Japan 4 Postgraduate Medical Education Center, Ehime University Graduate School of Medicine, Toon, Japan Copyright © 2024 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Download PDF CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported. AUTHOR CONTRIBUTIONS Conception or design: T.M., S.F., B.M., Y.H. Acquisition, analysis, or interpretation of data: T.M., S.F., O.Y., M.M., A.S., A.K., H.N., Y.N., Y.I., M.K., T.W., Y.Y., Y.K., Y.T., M.H., T.K., E.T., Y.I., M.A., Y.H. Drafting the work or revising: T.M. Final approval of the manuscript: all authors. FUNDING This research was funded by Japan Society for the Promotion of Science Kakenhi (JSPS KAKENHI), Grant Number 22K11804. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Values are presented as median (interquartile range) or percentage. To evaluate between-group differences, the Steel-Dwass test or a Tukey's test was used for continuous variables, b Chi-square test was used for categorical variables. P <0.05 was considered significant, c Duration of diabetes in patients with DM. HbA1c, glycosylated hemoglobin; NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; ALT, alanine aminotransferase; UA, uric acid; TC, total cholesterol; TG, triglyceride; DM, diabetes mellitus; NAS, activity score; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, alpha-glucosidase inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose transport protein 2 inhibitor. Differences were considered statistically significant at P <0.05. Model 1 was adjusted for age (years), sex, and hemoglobin (g/L), alanine aminotransferase (IU/L), and creatinine (μmol/L) levels. Model 2 was adjusted for body mass index (kg/m 2 ) and uric acid (μmol/L), total cholesterol (mmol/L), and triglyceride (mmol/L) levels. HbA1c, glycosylated hemoglobin; OR, odds ratio; CI, confidence interval. Differences were considered statistically significant at P <0.05. Model 1 was adjusted for age (years), sex, and hemoglobin (g/L), alanine aminotransferase (U/L), and creatinine (μmol/L) levels. Model 2 was adjusted for body mass index (kg/m 2 ) and uric acid (μmol/L), total cholesterol (mmol/L), and triglyceride (mmol/L) levels. HbA1c, glycosylated hemoglobin; NAS, NAFLD activity score; OR, odds ratio; CI, confidence interval. Values are presented as median (interquartile range). To evaluate between-group differences, the Mann-Whitney U test was used for continuous variables. P <0.05 was considered significant. HOMA-IR, homeostasis model assessment of insulin resistance; NAS, NAFLD activity score.

Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD

Glycemic Control Is Associated with Histological Findings of Nonalcoholic Fatty Liver Disease

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic Hepatitis B

Serum Proteomic Analysis Revealed Diagnostic Value of Hemoglobin for Nonalcoholic Fatty Liver Disease

Glycemic Measures and Development and Resolution of Nonalcoholic Fatty Liver Disease in Nondiabetic Individuals

Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic HBV infection

IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.

Postprandial Glucose is Correlated with an Increasing Risk of Liver Fibrosis in Chinese Patients with Nonalcoholic Fatty Liver Disease.

Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile

Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status

1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)

Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study

Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes

Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease

184-OR: Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM

Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis